Aspirin - Angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: A dose-related adverse effect of aspirin

Marco Guazzi, Roberto Brambilla, Giuseppe Rèina, Gabriele Tumminello, Maurizio D. Guazzi

Research output: Contribution to journalArticle

Abstract

Background: It is debated whether in patients with chronic heart failure (CHF), aspirin may contrast the clinical benefits of angiotensin-converting enzyme inhibitors (ACEIs). Two major unresolved issues in patients with CHF are whether these agents together can affect mortality and whether the interaction is related with the dose of aspirin. We aimed at exploring these possibilities. Methods: We evaluated more than 4000 hospitalizations with a principal discharge diagnosis of CHF from January 10, 1990, to December 31, 1999. The final analysis was restricted to 344 patients taking ACEIs who satisfied the selection criteria, in whom reliable information was available concerning drug therapy during follow-up. In these patients, treatment included no aspirin in 235 (group 1), a low dose (≤160 mg) in 45 (group 2), and a high dose (≥325 mg) in 64 (group 3). Results: During a mean follow-up of 37.6 months, there were 84 (36%) deaths in group 1, 15 (33%) in group 2, and 35 (55%) in group 3. By the Kaplan-Meier approach, survival was similar in groups 1 and 2, and significantly (P=.009) worse in group 3 compared with groups 1 and 2. After adjusting for potential confounding factors (including treatment, cause of heart disease, age, smoking, and diabetes mellitus), a time-dependent multivariate Cox proportional hazards regression analysis showed that the combination of high-dose aspirin with an ACEI was independently associated with the risk of death (hazard ratio, 1.03; P=.01) and that the combination of low-dose aspirin with an ACEI was not (hazard ratio, 1.02; P=.18). Conclusion: These results support the possibility that in some patients with CHF who are taking an ACEI, a dose-related effect of aspirin may adversely affect survival.

Original languageEnglish
Pages (from-to)1574-1579
Number of pages6
JournalArchives of Internal Medicine
Volume163
Issue number13
DOIs
Publication statusPublished - Jul 14 2003

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Aspirin
Heart Failure
Mortality
Survival
Patient Selection
Heart Diseases
Diabetes Mellitus
Hospitalization
Smoking
Regression Analysis
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Aspirin - Angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure : A dose-related adverse effect of aspirin. / Guazzi, Marco; Brambilla, Roberto; Rèina, Giuseppe; Tumminello, Gabriele; Guazzi, Maurizio D.

In: Archives of Internal Medicine, Vol. 163, No. 13, 14.07.2003, p. 1574-1579.

Research output: Contribution to journalArticle

Guazzi, Marco ; Brambilla, Roberto ; Rèina, Giuseppe ; Tumminello, Gabriele ; Guazzi, Maurizio D. / Aspirin - Angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure : A dose-related adverse effect of aspirin. In: Archives of Internal Medicine. 2003 ; Vol. 163, No. 13. pp. 1574-1579.
@article{6aeaf268e0e7474f83272e79456aa777,
title = "Aspirin - Angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: A dose-related adverse effect of aspirin",
abstract = "Background: It is debated whether in patients with chronic heart failure (CHF), aspirin may contrast the clinical benefits of angiotensin-converting enzyme inhibitors (ACEIs). Two major unresolved issues in patients with CHF are whether these agents together can affect mortality and whether the interaction is related with the dose of aspirin. We aimed at exploring these possibilities. Methods: We evaluated more than 4000 hospitalizations with a principal discharge diagnosis of CHF from January 10, 1990, to December 31, 1999. The final analysis was restricted to 344 patients taking ACEIs who satisfied the selection criteria, in whom reliable information was available concerning drug therapy during follow-up. In these patients, treatment included no aspirin in 235 (group 1), a low dose (≤160 mg) in 45 (group 2), and a high dose (≥325 mg) in 64 (group 3). Results: During a mean follow-up of 37.6 months, there were 84 (36{\%}) deaths in group 1, 15 (33{\%}) in group 2, and 35 (55{\%}) in group 3. By the Kaplan-Meier approach, survival was similar in groups 1 and 2, and significantly (P=.009) worse in group 3 compared with groups 1 and 2. After adjusting for potential confounding factors (including treatment, cause of heart disease, age, smoking, and diabetes mellitus), a time-dependent multivariate Cox proportional hazards regression analysis showed that the combination of high-dose aspirin with an ACEI was independently associated with the risk of death (hazard ratio, 1.03; P=.01) and that the combination of low-dose aspirin with an ACEI was not (hazard ratio, 1.02; P=.18). Conclusion: These results support the possibility that in some patients with CHF who are taking an ACEI, a dose-related effect of aspirin may adversely affect survival.",
author = "Marco Guazzi and Roberto Brambilla and Giuseppe R{\`e}ina and Gabriele Tumminello and Guazzi, {Maurizio D.}",
year = "2003",
month = "7",
day = "14",
doi = "10.1001/archinte.163.13.1574",
language = "English",
volume = "163",
pages = "1574--1579",
journal = "Archives of Internal Medicine",
issn = "0003-9926",
publisher = "American Medical Association",
number = "13",

}

TY - JOUR

T1 - Aspirin - Angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure

T2 - A dose-related adverse effect of aspirin

AU - Guazzi, Marco

AU - Brambilla, Roberto

AU - Rèina, Giuseppe

AU - Tumminello, Gabriele

AU - Guazzi, Maurizio D.

PY - 2003/7/14

Y1 - 2003/7/14

N2 - Background: It is debated whether in patients with chronic heart failure (CHF), aspirin may contrast the clinical benefits of angiotensin-converting enzyme inhibitors (ACEIs). Two major unresolved issues in patients with CHF are whether these agents together can affect mortality and whether the interaction is related with the dose of aspirin. We aimed at exploring these possibilities. Methods: We evaluated more than 4000 hospitalizations with a principal discharge diagnosis of CHF from January 10, 1990, to December 31, 1999. The final analysis was restricted to 344 patients taking ACEIs who satisfied the selection criteria, in whom reliable information was available concerning drug therapy during follow-up. In these patients, treatment included no aspirin in 235 (group 1), a low dose (≤160 mg) in 45 (group 2), and a high dose (≥325 mg) in 64 (group 3). Results: During a mean follow-up of 37.6 months, there were 84 (36%) deaths in group 1, 15 (33%) in group 2, and 35 (55%) in group 3. By the Kaplan-Meier approach, survival was similar in groups 1 and 2, and significantly (P=.009) worse in group 3 compared with groups 1 and 2. After adjusting for potential confounding factors (including treatment, cause of heart disease, age, smoking, and diabetes mellitus), a time-dependent multivariate Cox proportional hazards regression analysis showed that the combination of high-dose aspirin with an ACEI was independently associated with the risk of death (hazard ratio, 1.03; P=.01) and that the combination of low-dose aspirin with an ACEI was not (hazard ratio, 1.02; P=.18). Conclusion: These results support the possibility that in some patients with CHF who are taking an ACEI, a dose-related effect of aspirin may adversely affect survival.

AB - Background: It is debated whether in patients with chronic heart failure (CHF), aspirin may contrast the clinical benefits of angiotensin-converting enzyme inhibitors (ACEIs). Two major unresolved issues in patients with CHF are whether these agents together can affect mortality and whether the interaction is related with the dose of aspirin. We aimed at exploring these possibilities. Methods: We evaluated more than 4000 hospitalizations with a principal discharge diagnosis of CHF from January 10, 1990, to December 31, 1999. The final analysis was restricted to 344 patients taking ACEIs who satisfied the selection criteria, in whom reliable information was available concerning drug therapy during follow-up. In these patients, treatment included no aspirin in 235 (group 1), a low dose (≤160 mg) in 45 (group 2), and a high dose (≥325 mg) in 64 (group 3). Results: During a mean follow-up of 37.6 months, there were 84 (36%) deaths in group 1, 15 (33%) in group 2, and 35 (55%) in group 3. By the Kaplan-Meier approach, survival was similar in groups 1 and 2, and significantly (P=.009) worse in group 3 compared with groups 1 and 2. After adjusting for potential confounding factors (including treatment, cause of heart disease, age, smoking, and diabetes mellitus), a time-dependent multivariate Cox proportional hazards regression analysis showed that the combination of high-dose aspirin with an ACEI was independently associated with the risk of death (hazard ratio, 1.03; P=.01) and that the combination of low-dose aspirin with an ACEI was not (hazard ratio, 1.02; P=.18). Conclusion: These results support the possibility that in some patients with CHF who are taking an ACEI, a dose-related effect of aspirin may adversely affect survival.

UR - http://www.scopus.com/inward/record.url?scp=0038494006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038494006&partnerID=8YFLogxK

U2 - 10.1001/archinte.163.13.1574

DO - 10.1001/archinte.163.13.1574

M3 - Article

C2 - 12860580

AN - SCOPUS:0038494006

VL - 163

SP - 1574

EP - 1579

JO - Archives of Internal Medicine

JF - Archives of Internal Medicine

SN - 0003-9926

IS - 13

ER -